Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Nab-paclitaxel
Drug: Cisplatin
Drug: 5Fluorouracil
Drug: Docetaxel
Drug: carboplatin
Drug: Cyclophosphamide
Biological: ETBX-011
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-4000
Biological: GI-6301
Drug: Aldoxorubicin
Drug: Avelumab
Drug: ALT-803
Biological: haNK

First Posted Date: 2018-07-02

Last Posted Date: 2022-04-05

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT03574649

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Phase II Umbrella Study Directed by Next Generation Sequencing

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Avitinib Maleate
Drug: Afatinib
Drug: Pyrotinib Maleate
Drug: Pirotinib
Drug: Nimotuzumab
Drug: Sintilimab
Drug: Crizotinib
Drug: X-396
Drug: AZD3759
Drug: Gemcitabine
Drug: Pemetrexed
Drug: Cisplatin
Drug: Chidamide
Drug: Carboplatin

First Posted Date: 2018-07-02

Last Posted Date: 2022-12-06

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 400

Registration Number: NCT03574402

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Phase 1

Active, not recruiting

Conditions: Neoplasms

Interventions: Biological: MK-4830A
Drug: MK-4830
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Lenvatinib
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2018-06-21

Last Posted Date: 2024-11-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 442

Registration Number: NCT03564691

Locations: 🇨🇦
Princess Margaret Cancer Centre ( Site 0033), Toronto, Ontario, Canada
🇺🇸
Seattle Cancer Care Alliance ( Site 0010), Seattle, Washington, United States
🇺🇸
University of California at San Francisco ( Site 0004), San Francisco, California, United States

and more 34 locations

A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer

Not Applicable

Conditions: Cervical Cancer

Interventions: Drug: Cisplatin

First Posted Date: 2018-06-18

Last Posted Date: 2019-01-22

Lead Sponsor: Sichuan University

Target Recruit Count: 58

Registration Number: NCT03559803

Locations: 🇨🇳
Guizhou Province People's Hospital, Guizhou, Guizhou, China
🇨🇳
West China Hospital, Sichuan University, Chendu, Sichuan, China

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: Nivolumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2018-06-15

Last Posted Date: 2024-06-27

Lead Sponsor: Matthew Galsky

Target Recruit Count: 76

Registration Number: NCT03558087

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Univerity of Southern California, Los Angeles, California, United States
🇺🇸
Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania, United States

and more 4 locations

By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Cisplatin
Drug: Nimotuzumab

First Posted Date: 2018-06-14

Last Posted Date: 2018-11-02

Lead Sponsor: Guiyang Medical University

Target Recruit Count: 180

Registration Number: NCT03557112

Locations: 🇨🇳
Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Phase 2

Recruiting

Conditions: Metastatic Urothelial Cancer

Interventions: Drug: Sacituzumab Govitecan-hziy
Drug: Zimberelimab
Drug: Cisplatin
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Domvanalimab
Drug: Avelumab
Drug: Gemcitabine
Drug: Enfortumab Vedotin

First Posted Date: 2018-06-06

Last Posted Date: 2024-12-11

Lead Sponsor: Gilead Sciences

Target Recruit Count: 643

Registration Number: NCT03547973

Locations: 🇺🇸
The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 132 locations

HIPEC After Initial CRS in Patients Who Have Received NACT

Phase 1

Recruiting

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Carcinoma

Interventions: Drug: Cisplatin

First Posted Date: 2018-05-30

Last Posted Date: 2022-11-02

Lead Sponsor: Northwell Health

Target Recruit Count: 15

Registration Number: NCT03540017

Locations: 🇺🇸
Long Island Jewish Medical Center, New Hyde Park, New York, United States

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Pancreatic Neoplasms
Digestive System Neoplasm
Adenocarcinoma
Pancreatic Diseases
Neoplasm, Glandular
Neoplasms Pancreatic
Digestive System Disease

Interventions: Drug: Nab-paclitaxel
Drug: Gemcitabine
Drug: Capecitabine
Drug: Cisplatin
Drug: Irinotecan

First Posted Date: 2018-05-24

Last Posted Date: 2024-12-31

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 48

Registration Number: NCT03535727

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread

Phase 3

Recruiting

Conditions: Cervical Cancer TNM Staging Regional Lymph Nodes (N)

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Cisplatin
Radiation: Radiotherapy

First Posted Date: 2018-05-23

Last Posted Date: 2023-09-21

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 310

Registration Number: NCT03534713

Locations: 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷
CH Lyon Sud, Pierre-Bénite, France
🇫🇷
Institut de Cancérologie de l'Ouest - Nantes, Saint-Herblain, France

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy